Skip to main content
Top
Published in: Diabetologia 10/2005

01-10-2005 | Article

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

Authors: A. Dawson, A. D. Morris, A. D. Struthers

Published in: Diabetologia | Issue 10/2005

Login to get access

Abstract

Aims/hypothesis

Patients with type 2 diabetes mellitus are at greater cardiovascular risk than the general population. Although it is widely acknowledged that diabetes is a risk factor for coronary artery disease, the increased prevalence of potentially lethal left ventricular abnormalities in this population is less well appreciated.

Methods

We carried out an echocardiographic study of 500 subjects with type 2 diabetes mellitus to assess the prevalence of left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction (LVSD). We also assessed whether abnormalities in diastolic filling parameters were present.

Results

Of the 371 patients in whom left ventricular mass could be successfully assessed, 264 had LVH (71%). Left ventricular systolic dysfunction was much less common, being present in 16/385 patients (4.2%). Long axis contraction was abnormal in 29/429 patients (6.8%). Diastolic filling abnormalities were present in 178/435 (41%) of patients who could be classified using the selected criteria.

Conclusions

We conclude that left ventricular abnormalities are common in type 2 diabetic patients. As medical therapy is available for both LVH and LVSD and has been demonstrated to reduce cardiovascular death, these left ventricular abnormalities could be ideal targets for screening, followed by selective therapeutic intervention.
Appendix
Available only for authorised users
Literature
1.
go back to reference King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMed King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMed
2.
go back to reference Laakso M (1999) Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937–942PubMed Laakso M (1999) Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937–942PubMed
3.
go back to reference Goraya TY, Leibson CL, Palumbo PJ et al (2002) Coronary atherosclerosis in diabetes mellitus. A population-based autopsy study. J Am Coll Cardiol 40:946–953PubMed Goraya TY, Leibson CL, Palumbo PJ et al (2002) Coronary atherosclerosis in diabetes mellitus. A population-based autopsy study. J Am Coll Cardiol 40:946–953PubMed
4.
go back to reference Dortimer AC, Shenoy PN, Shiroff RA et al (1978) Diffuse coronary artery disease in diabetic patients. Fact or fiction? Circulation 57:133–136PubMed Dortimer AC, Shenoy PN, Shiroff RA et al (1978) Diffuse coronary artery disease in diabetic patients. Fact or fiction? Circulation 57:133–136PubMed
5.
go back to reference Woodfield S, Lundergan C, Reiner J et al (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 28:1661–1669PubMed Woodfield S, Lundergan C, Reiner J et al (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 28:1661–1669PubMed
6.
go back to reference Falcone C, Nespoli L, Geroldi D et al (2003) Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. Int J Cardiol 90:219–227PubMed Falcone C, Nespoli L, Geroldi D et al (2003) Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. Int J Cardiol 90:219–227PubMed
7.
go back to reference Rytter L, Troelsen S, Beck-Nielsen H (1985) Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 8:230–234PubMed Rytter L, Troelsen S, Beck-Nielsen H (1985) Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 8:230–234PubMed
8.
go back to reference Struthers AD, Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430–1432PubMed Struthers AD, Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430–1432PubMed
9.
go back to reference Sullivan JM, Zwaag RV, El-Zeky F, Ramanathan KB, Mirvis DM (1993) Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 22:508–513PubMed Sullivan JM, Zwaag RV, El-Zeky F, Ramanathan KB, Mirvis DM (1993) Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 22:508–513PubMed
10.
go back to reference Lorell BH, Carabello BA (2000) Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation 102:470–479PubMed Lorell BH, Carabello BA (2000) Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation 102:470–479PubMed
11.
go back to reference Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566PubMed Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566PubMed
12.
go back to reference Vakilli BA, Okin PM, Devereux RB (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141:334–341PubMed Vakilli BA, Okin PM, Devereux RB (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141:334–341PubMed
13.
go back to reference Kannel WB, Abbott RD (1986) A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J 111:391–397PubMed Kannel WB, Abbott RD (1986) A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J 111:391–397PubMed
14.
go back to reference Lauer M, Evans J, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70:1180–1184PubMed Lauer M, Evans J, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70:1180–1184PubMed
15.
go back to reference McDonagh TA, Cunningham AD, Morrison CE et al (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86:21–26PubMed McDonagh TA, Cunningham AD, Morrison CE et al (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86:21–26PubMed
16.
go back to reference Willenheimer R, Cline C, Erhardt L, Israelsson B (1997) Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart 78:230–236PubMed Willenheimer R, Cline C, Erhardt L, Israelsson B (1997) Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart 78:230–236PubMed
17.
go back to reference Schillaci G, Pasqualini L, Verdecchia P et al (2002) Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 39:2005–2011PubMed Schillaci G, Pasqualini L, Verdecchia P et al (2002) Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 39:2005–2011PubMed
18.
go back to reference Møller JE, Søndergaard E, Seward JB, Appleton CP, Egstrup K (2000) Ratio of left ventricular peak E-wave velocity to flow propagation velocity assessed by color M-mode Doppler echocardiography in first myocardial infarction. Prognostic and clinical implications. J Am Coll Cardiol 35:363–370PubMed Møller JE, Søndergaard E, Seward JB, Appleton CP, Egstrup K (2000) Ratio of left ventricular peak E-wave velocity to flow propagation velocity assessed by color M-mode Doppler echocardiography in first myocardial infarction. Prognostic and clinical implications. J Am Coll Cardiol 35:363–370PubMed
19.
go back to reference Poirier P, Bogarty P, Garneau C, Marois L, Dumesnil J (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Diabetes Care 24:5–10PubMed Poirier P, Bogarty P, Garneau C, Marois L, Dumesnil J (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Diabetes Care 24:5–10PubMed
20.
go back to reference World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, World Health Organization, Geneva, pp 1–59 World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, World Health Organization, Geneva, pp 1–59
21.
go back to reference Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458PubMed Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458PubMed
22.
go back to reference Schiller NB, Shah PM, Crawford M, for the American Society of Echocardiography Committee on Standards, Sub-Committee on Quantitation of Two Dimensional Echocardiograms et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2:358–367PubMed Schiller NB, Shah PM, Crawford M, for the American Society of Echocardiography Committee on Standards, Sub-Committee on Quantitation of Two Dimensional Echocardiograms et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2:358–367PubMed
23.
go back to reference European Study Group on Diastolic Heart Failure (1998) How to diagnose diastolic heart failure. Eur Heart J 19:990–1003 European Study Group on Diastolic Heart Failure (1998) How to diagnose diastolic heart failure. Eur Heart J 19:990–1003
24.
go back to reference Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK (1995) The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273:1592–1597PubMed Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK (1995) The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273:1592–1597PubMed
25.
go back to reference Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54PubMed Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54PubMed
26.
go back to reference Muiesan M, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E (1995) Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13:1091–1095PubMed Muiesan M, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E (1995) Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13:1091–1095PubMed
27.
go back to reference Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB (2002) Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15:1021–1028PubMed Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB (2002) Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15:1021–1028PubMed
28.
go back to reference Galderisi M, Anderson KM, Wilson PWF, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 68:85–89PubMed Galderisi M, Anderson KM, Wilson PWF, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 68:85–89PubMed
29.
go back to reference Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13PubMed Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13PubMed
30.
go back to reference Devereux R, Pickering T, Harshfield G et al (1983) Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 68:470–476PubMed Devereux R, Pickering T, Harshfield G et al (1983) Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 68:470–476PubMed
31.
go back to reference Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B (2000) Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 35:13–18PubMed Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B (2000) Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 35:13–18PubMed
32.
go back to reference Karason K, Sjöström L, Wallentin I, Peltonen M (2003) Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J 24:1500–1505PubMed Karason K, Sjöström L, Wallentin I, Peltonen M (2003) Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J 24:1500–1505PubMed
33.
go back to reference Hill D, Millner D (1985) Insulin as a growth factor. Pediatr Res 19:879–886PubMed Hill D, Millner D (1985) Insulin as a growth factor. Pediatr Res 19:879–886PubMed
34.
go back to reference Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374–382PubMed Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374–382PubMed
35.
go back to reference Gosse P, Sheridan DJ, Zannad F et al (2000) Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study. J Hypertens 18:1465–1475PubMed Gosse P, Sheridan DJ, Zannad F et al (2000) Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study. J Hypertens 18:1465–1475PubMed
36.
go back to reference Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259
37.
go back to reference Mathew J, Sleight P, Lonn E for the Heart Outcomes Prevention Evaluation (HOPE) Investigators et al (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621PubMed Mathew J, Sleight P, Lonn E for the Heart Outcomes Prevention Evaluation (HOPE) Investigators et al (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621PubMed
38.
go back to reference Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F (2000) Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35:580–586PubMed Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F (2000) Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35:580–586PubMed
39.
go back to reference Wachtell K, Bella JN, Liebson PR et al (2000) Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 35:6–12PubMed Wachtell K, Bella JN, Liebson PR et al (2000) Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 35:6–12PubMed
40.
go back to reference de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH (1995) Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056–1062PubMed de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH (1995) Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056–1062PubMed
41.
go back to reference Ghali JK, Liao Y, Cooper RS (1998) Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 31:1635–1640PubMed Ghali JK, Liao Y, Cooper RS (1998) Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 31:1635–1640PubMed
42.
go back to reference Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S (2003) Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 34:2380–2384PubMed Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S (2003) Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 34:2380–2384PubMed
43.
go back to reference Krumholz HM, Larson M, Levy D (1995) Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 25:879–884PubMed Krumholz HM, Larson M, Levy D (1995) Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 25:879–884PubMed
44.
go back to reference Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA (2001) Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87:320–323PubMed Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA (2001) Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87:320–323PubMed
45.
go back to reference Andersen N, Poulsen S, Eiskjær H, Poulsen P (2003) Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin Sci 105:56–59 Andersen N, Poulsen S, Eiskjær H, Poulsen P (2003) Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin Sci 105:56–59
46.
go back to reference Liu JE, Palmieri V, Roman MJ et al (2001) The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37:1943–1949PubMed Liu JE, Palmieri V, Roman MJ et al (2001) The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37:1943–1949PubMed
47.
go back to reference Eren M, Gorgulu S, Uslu N, Celik S, Dagdeviren B, Tezel T (2004) Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart 90:37–43PubMed Eren M, Gorgulu S, Uslu N, Celik S, Dagdeviren B, Tezel T (2004) Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart 90:37–43PubMed
48.
go back to reference Diamant M, Lamb H, Groeneveld Y et al (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328–335PubMed Diamant M, Lamb H, Groeneveld Y et al (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328–335PubMed
49.
go back to reference EUROASPIRE I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357:995–1001 EUROASPIRE I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357:995–1001
50.
go back to reference Hall L, Jung R, Leese G (2003) Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 326:251–252PubMed Hall L, Jung R, Leese G (2003) Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 326:251–252PubMed
51.
go back to reference The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997
52.
go back to reference Koren M, Devereux R, Casale P, Savage D, Laragh J (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345–352PubMed Koren M, Devereux R, Casale P, Savage D, Laragh J (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345–352PubMed
53.
go back to reference Schirmer H, Lunde P, Rasmussen K (1999) Prevalence of left ventricular hypertrophy in a general population: the Tromso Study. Eur Heart J 20:429–438PubMed Schirmer H, Lunde P, Rasmussen K (1999) Prevalence of left ventricular hypertrophy in a general population: the Tromso Study. Eur Heart J 20:429–438PubMed
54.
go back to reference Devereux RB, Palmieri V, Liu JE et al (2002) Progressive hypertrophy regression with sustained pressure reduction in hypertension: the losartan intervention for endpoint study. J Hypertens 20:1445–1450PubMed Devereux RB, Palmieri V, Liu JE et al (2002) Progressive hypertrophy regression with sustained pressure reduction in hypertension: the losartan intervention for endpoint study. J Hypertens 20:1445–1450PubMed
55.
go back to reference Kuroda T, Shiina A, Tsuruda KT et al (1991) Assessment of hypertensive heart by 2-dimensional echocardiography in mass screening. Jpn Circ J 55:365–376PubMed Kuroda T, Shiina A, Tsuruda KT et al (1991) Assessment of hypertensive heart by 2-dimensional echocardiography in mass screening. Jpn Circ J 55:365–376PubMed
56.
go back to reference Witham MD, Davies JI, Dawson A, Davey PG, Struthers AD (2004) Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations. QJM 97:87–93PubMed Witham MD, Davies JI, Dawson A, Davey PG, Struthers AD (2004) Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations. QJM 97:87–93PubMed
Metadata
Title
The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus
Authors
A. Dawson
A. D. Morris
A. D. Struthers
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1896-y

Other articles of this Issue 10/2005

Diabetologia 10/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.